Quick Facts

• Key Therapeutic Domain: Addresses moderate to severe vasomotor symptoms associated with menopause.
• Additional Use: Manages certain symptoms of vulvar and vaginal atrophy related to menopause.
• Prevention: May be utilized to support the prevention of postmenopausal bone thinning (osteoporosis) in women at significant risk.

---

Эстрофем (which contains estradiol) is utilized as a form of hormone replacement therapy to address specific conditions linked to reduced levels of estrogen in the body, primarily in postmenopausal women. The medication is prescribed to manage moderate to severe vasomotor symptoms, which commonly manifest as hot flushes and night sweats.

It is also a therapeutic option for the management of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause, such as dryness, itching, and burning. For these specific symptoms, healthcare professionals may initially consider topical vaginal products.

Furthermore, the treatment may be used for the prevention of postmenopausal osteoporosis in women who are at considerable risk of bone fracture and for whom non-estrogen therapies are considered unsuitable. Its general use is to replace estrogen that the body no longer produces naturally. All treatment decisions should be guided by a healthcare professional.

Regulatory References

1. NIH DailyMed guidance

Official Population Eligibility for Эстрофем (Estradiol)

The use of Эстрофем is strictly defined by regulatory criteria, limiting its use primarily to postmenopausal women to address estrogen deficiency symptoms. The drug is contraindicated and must not be used by specific populations due to significant risk factors.

---

Absolute Contraindications (Must Not Use)

Condition / History
Known, suspected, or history of breast cancer or other estrogen-dependent malignancies
Active or history of venous thromboembolism (VTE), arterial thromboembolic disease (e.g., MI, stroke), or thrombophilic disorders
Acute liver disease or uncorrected abnormal liver function tests
Undiagnosed abnormal genital bleeding or untreated endometrial hyperplasia
Known or suspected pregnancy

---

Special Population Restrictions

Use is not indicated or not established in the pediatric population. For women 65 years of age and older, clinical experience is limited, and an increased risk of probable dementia has been reported. The medicine is not recommended for women who are breastfeeding. Conditional use requires careful observation for patients with conditions such as renal dysfunction, hypertension, diabetes mellitus, and a history of endometriosis.

Interactions with other medicines and products

The effectiveness and safety of estradiol (Estrofem) can be significantly affected by co-administered medications and substances. The primary interaction pathway involves the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver, which metabolizes estradiol.

Documented Pharmacokinetic Interactions

Interaction Type	Interacting Substances (Examples)	Resulting Effect on Estradiol Levels
Enzyme Inducers	Rifampin, Phenobarbital, Carbamazepine, St. John’s Wort	Decrease (potential loss of efficacy)
Enzyme Inhibitors	Ketoconazole, Itraconazole, Ritonavir, Grapefruit Juice	Increase (potential for increased adverse effects)

Pharmacodynamic and Other Interactions

• Corticosteroids: Estradiol can decrease the metabolic clearance of corticosteroids, potentially increasing their plasma concentrations and effects.
• Thyroid Hormone Replacement: Estrogens increase the level of Thyroid Binding Globulin (TBG). This may necessitate an increase in the dose of thyroid hormone replacement (e.g., Levothyroxine) for patients with hypothyroidism.
• Ospemifene: Regulatory documents generally list this combination as one that must not be co-administered.

Interaction Context Notes

Patients with Hypertriglyceridemia require special consideration, as estrogen therapy may be associated with severe elevations of plasma triglycerides. Estrogens may also interfere with the results of certain laboratory tests, including coagulation and thyroid function tests.

Éstrofem is the brand name for Estradiol, a synthetic form of the endogenous estrogen hormone. Its pharmacodynamic mechanism is centered on its function as a high-affinity agonist of the Estrogen Receptors (ERs), specifically ER alpha (alpha) and ER beta (beta).

The primary action, termed the genomic pathway, involves the drug binding to these nuclear receptors. This drug-receptor complex subsequently dimerizes and binds to specific DNA sequences known as Estrogen Response Elements (EREs) on target gene promoters. This binding event modulates DNA transcription, altering the rate of protein synthesis and leading to modified intracellular processes.

Simultaneously, the drug engages non-genomic signaling cascades through interaction with membrane-associated receptors, such as the G Protein-Coupled Estrogen Receptor (GPER). This triggers rapid intracellular signaling sequences that bypass the nucleus, influencing cytoplasmic activities like ion channel function and second-messenger systems. These combined actions result in predictable, system-level physiological modulation in estrogen-sensitive tissues.

How to Use Эстрофем: Official Administration Guidelines

Эстрофем (Estradiol hemihydrate) is an oral medication that must be used strictly according to the procedures outlined in the product prescribing information. The goal of therapy is to utilize the lowest effective dose for the shortest treatment duration required.

---

Dosing and Route of Administration

Instruction Category	Detail
Route of Administration	The drug is taken orally (by mouth).
Dose and Frequency	The usual dose is one tablet once daily (either 1 mg or 2 mg). The regimen is typically continuous (without interruption).
Tablet Intake	The tablets must be swallowed whole with liquid and should be taken preferably at the same time each day for consistency.

---

Use Patterns and Procedural Rules

The correct procedural use is highly dependent on whether the patient has an intact uterus:

• For Women with a Uterus: Эстрофем must be combined with a progestagen for at least 10 to 14 days of a 28-day cycle. This is a mandatory combination regimen.
• For Women Without a Uterus: Эстрофем is typically used as an estrogen-only continuous regimen, and treatment can be started on any convenient day.

Handling a Missed Dose

If a dose is forgotten, it must be taken as soon as possible within 12 hours of the usual time. If more than 12 hours have passed, the missed dose must be skipped, and the patient resumes the regular schedule the following day. A double dose must not be taken to compensate for a missed one.

Overview of Clinical Studies and Research for Эстрофем

This section provides a simple look at the research and clinical studies that was studied for use of Эстрофем (estradiol). Understanding the evidence means knowing what types of studies have been conducted, what outcomes was observed in, and what aspects of the treatment are still being observed or remain uncertain. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence for the Management of Vasomotor Symptoms (Hot Flushes and Night Sweats)

The research exploring this clinical context involves Randomized Controlled Trials (RCTs), and subsequent reviews of multiple studies (Meta-analyses). The medication was studied for use in postmenopausal women who were experiencing moderate to severe hot flushes and night sweats. These trials constitute the primary research designs and are relevant in evidence describing how symptoms are measured. The research examined outcomes related to physical discomfort, specifically tracking outcomes describing episodic or acute changes. What remains uncertain is how these measured outcomes are sustained over very long periods. Long-term effects are not fully established regarding changes in VMS beyond the initial 12-month study periods.

---

Evidence for Addressing Vulvar and Vaginal Atrophy Symptoms

Research exploring this use involves a mix of RCTs and studies that compare Эстрофем to a placebo or to other local, topical treatments. The medication was evaluated in postmenopausal women who had symptoms like dryness, burning, and discomfort related to vulvar and vaginal atrophy. Studies explored outcomes linked to inflammatory or irritative states. Researchers monitored patient-reported outcomes describing perceived discomfort and also looked at physical measures, such as changes in the health of vaginal tissues and pH levels. The evidence is limited concerning the long-term durability of symptom patterns beyond one year. Comparative evidence to local, topical treatments was explored.

---

Evidence for the Prevention of Postmenopausal Bone Thinning (Osteoporosis)

Research in this area is characterized by long-term studies, including both RCTs and extensive observational cohorts. Эстрофем was observed in postmenopausal women at a considerable risk of fracture. Studies examined outcomes reflecting daily functioning or activity level by measuring the long-term changes in Bone Mineral Density (BMD) and tracking the incidence rate of various bone fractures.

Key Studies & References

1. DailyMed: Estradiol Tablet - official prescribing information and patient instructions

Common questions about Эстрофем (FAQ)

---

Q: Does this medicine make you feel sleepy?

Official regulatory documents indicate that common adverse reactions reported in adults include somnolence (sleepiness) and dizziness. This type of side effect may affect the ability to perform activities that require mental alertness, so caution is advised.

---

Q: Can this medication cause weight gain?

According to the official product information, weight gain is listed as one of the most common adverse reactions reported in adults. In pediatric patients, both increased weight and increased appetite are identified as common side effects.

---

Q: Is it safe to take this long-term?

The official label discusses the importance of gradual discontinuation, noting that rapid stopping of the drug can lead to withdrawal symptoms or an increase in seizure frequency. The labeling describes gradual discontinuation, which is a common approach for medications used for long-term conditions.

---

Q: Can this medication make me feel 'high' or euphoric?

The official product information lists 'thinking abnormal'—primarily difficulty with concentration and attention—as a common side effect. Separately, the labeling notes that people who misuse the drug may abuse it because it can produce feelings of euphoria or being 'high'.

---

Q: Can children 2 years old use this?

Official labeling indicates the medication is approved as an add-on therapy for partial-onset seizures in patients 1 month of age and older. Specific dosing information is available for young pediatric patients, including those in the 1 month to less than 4 years old age group, as described in the full product information.

How to Store and Dispose of Эстрофем?

The storage and disposal of Эстрофем (estradiol tablets) must strictly follow the requirements detailed in the official regulatory documentation to maintain product stability and ensure safety.

Storage Requirement	Official Mandate
Temperature	Store below 25 C (Do not refrigerate).
Environment	Keep in a cool, dry, dark place.
Packaging	Keep the medicine in its original container to protect it from light and moisture.
Stability	Do not use the tablets after the expiry date printed on the packaging.
Child Safety	Keep this medicine out of the sight and reach of children.

For disposal, the regulatory instruction is to not throw unused or expired tablets into household rubbish or flush them down the toilet (wastewater). The proper protocol is to ask a pharmacist for advice on disposal through appropriate medicine take-back programs.